Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2017;12:6–11.

CAS  Article  Google Scholar 

Trickey A, May MT, Vehreschild J-J, Obel N, Gill MJ, Crane HM, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–56.

Article  Google Scholar 

Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK, CDC, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 2004;53:1–112.

Google Scholar 

Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007; vol. 19. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2007-vol-19.pdf. Published 2009. Accessed [April 2021].

Centers for Disease Control and Prevention. HIV Surveillance Report, 2018 (Updated); vol.31. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-updated-vol-31.pdf. Published May 2020. Accessed [April 2021].

Shiels MS, Islam JY, Rosenberg PS, Hall HI, Jacobson E, Engels EA. Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030. Ann Intern Med. 2018;168:866.

Article  Google Scholar 

Wing EJ. HIV and aging. Int J Infect Dis. 2016;53:61–8.

Article  Google Scholar 

Mitsuyasu RT. Non-AIDS-defining cancers. Top Antivir Med. 2014;22:660–5. This paper gives the overall review of the literature on the evolving HIV epidemiology with regard to NADCs, and focuses on cancer screening and prevention in PLWH, as well as, increased mortality, and risk factors involved in the pathogenesis of NADCs.

Park LS, Hernández-Ramírez RU, Silverberg MJ, Crothers K, Dubrow R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS. 2016;30:273–91.

CAS  Article  Google Scholar 

Smetana K Jr, Lacina L, Szabo P, Dvořánková B, Brož P, Šedo A. Ageing as an important risk factor for cancer. Anticancer Res. 2016;36:5009–18.

CAS  Article  Google Scholar 

Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess cancers among HIV-infected people in the United States. JNCI J Natl Cancer Inst [Internet]. 2015 [cited 2020 Aug 20];107. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju503

Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. JAIDS J Acquir Immune Defic Syndr. 2009;52:611–22.

Article  Google Scholar 

Coghill AE, Suneja G, Rositch AF, Shiels MS, Engels EA. HIV infection, cancer treatment regimens, and cancer outcomes among elderly adults in the United States. JAMA Oncol. 2019;5:e191742 This study uses SEER-Medicare data to understand the effect of HIV on mortality, cancer-specific mortality, and relapse of cancer. Even after accounting for the effect of treatment, PLWH and cancer had higher cancer-specific mortality than HIVuninfected cancer patients. This suggests that rather than healthcare disparities, that HIVassociated immunosuppression could be associated with worse cancer outcomes in PLWH

Corrigan KL, Wall KC, Bartlett JA, Suneja G. Cancer disparities in people with HIV: A systematic review of screening for non-AIDS–defining malignancies. Cancer. 2019;12(5):843–53 This systematic review compiles findings from various studies on the screening disparities for NADCs in PLWH in high-income countries. The nine-study systematic review found inconclusive evidence on differential screening practices by HIV status, but determined that access to care, insurance status, education, and income levels were critical risk factors for poor cancer screening in PLWH.

Article  Google Scholar 

Suneja G, Coghill A. Cancer care disparities in people with HIV in the United States. Curr Opin HIV AIDS. 2017;12:63–8.

Article  Google Scholar 

Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.

Article  Google Scholar 

Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153:452–60.

Article  Google Scholar 

Sigel K, Wisnivesky J, Shahrir S, Brown ST, Justice A, Kim J, et al. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS. 2014;28:1007–14.

Article  Google Scholar 

Goedert JJ, Hosgood HD, Biggar RJ, Strickler HD, Rabkin CS. Screening for cancer in persons living with HIV infection. Trends Cancer. 2016;2:416–28.

Article  Google Scholar 

Human Papillomavirus Disease | Adult and Adolescent Opportunistic Infection | ClinicalInfo [Internet]. [cited 2021 Apr 4]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/human-papillomavirus-disease

de Pokomandy A, Burchell AN, Salters K, Ding E, O’Brien N, Bakombo DM, et al. Cervical cancer screening among women living with HIV: a cross-sectional study using the baseline questionnaire data from the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS). CMAJ Open. 2019;7:E217–26.

Article  Google Scholar 

Preston-Martin S, Kirstein LM, Pogoda JM, Rimer B, Melnick S, Masri-Lavine L, et al. Use of mammographic screening by HIV-infected women in the Women’s Interagency HIV Study (WIHS). Prev Med. 2002;34:386–92.

Article  Google Scholar 

Marcus JL, Chao CR, Leyden WA, Xu L, Klein DB, Horberg MA, et al. Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. JAIDS J Acquir Immune Defic Syndr. 2014;66:495–502.

Article  Google Scholar 

Shiels MS, Goedert JJ, Moore RD, Platz EA, Engels EA. Reduced risk of prostate cancer in U.S. men with AIDS. Cancer Epidemiol Biomarkers Prev. 2010;19:2910–5.

Article  Google Scholar 

Fantry LE, Nowak RG, Fisher LH, Cullen NR, Yimgang DP, Stafford KA, et al. Colonoscopy findings in HIV-infected men and women from an urban U.S. cohort compared with non-HIV-infected men and women. AIDS Res Hum Retroviruses. 2016;32:860–7.

Article  Google Scholar 

Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172–2.

Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21:617–23.

Article  Google Scholar 

Gross AM, Jaeger PA, Kreisberg JF, Licon K, Jepsen KL, Khosroheidari M, et al. Methylome-wide analysis of chronic HIV infection reveals five-year increase in biological age and epigenetic targeting of HLA. Mol Cell. 2016;62:157–68.

CAS  Article  Google Scholar 

Jacob JA. Men with HIV age faster according to DNA methylation study. JAMA. 2016;316:135.

Article  Google Scholar 

Althoff KN, KA MG, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015;60:627–38 Using the VACS data, this study compares the risk and median age at diagnosis for aging-associated diseases, including cancer. Evidence showed though there was an increased risk for NADCs in PLWH, but there was no clinically meaningful difference in age at diagnosis for NADCs when adjusting for the age distributions in the population by HIV status.

Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. :332.

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17:1471–4.

Article  Google Scholar 

Andrews J, Billett R, Brandt M, Callaghan C, Cheney H, Groves C, et al. SEER Program Coding and Staging Manual. 2016;2016:204.

Google Scholar 

Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS. 2007;21:207–13.

Article  Google Scholar 

Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, Engels EA. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS. 2013;27:459–68.

Article  Google Scholar 

Suneja G, Shiels MS, Angulo R, Copeland GE, Gonsalves L, Hakenewerth AM, et al. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol. 2014;32:2344–50.

Article  Google Scholar 

Shiels MS, Copeland G, Goodman MT, Harrell J, Lynch CF, Pawlish K, et al. Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients: Cancer Stage in Immunosuppressed Patients. Cancer. 2015;121:2063–71 Using the HIV/AIDS Cancer Match study, the authors demonstrated that cancer (melanoma and bladder) was detected at more advanced stages in PLWH and they were more likely to be diagnosed with distant stage cancer (lung, breast, prostate) than immunocompetent cancer patients. PLWH had higher odds of advanced and distant stage cancers even compared to organ transplant recipients.

Rositch AF, Jiang S, Coghill AE, Suneja G, Engels EA. Disparities and determinants of cancer treatment in elderly Americans living with human immunodeficiency virus/AIDS. Clin Infect Dis [Internet]. 2018 [cited 2019 Sep 13]; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy373/4987477. This SEER-Medicare study shows reduced cancer treatment rates in PLWH, where the lowest rates were in the 65-70 age-group. The paper also highlights the direct (HIV infection) and indirect (cancer stage and comorbidities) effects on cancer treatment in PLWH. Unlike cancer screening, cancer stage, and comorbidities, it was time to treatment and HIV infection that contributed to the cancer treatment disparity in PLWH.

Suneja G, Lin CC, Simard EP, Han X, Engels EA, Jemal A. Disparities in cancer treatment among patients infected with the human immunodeficiency virus: cancer treatment in HIV-infected individuals. Cancer. 2016;122:2399–407.

CAS  Article  Google Scholar 

Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol. 2015;33:2376–83.

Article  Google Scholar 

Marcus JL, Chao C, Leyden WA, Xu L, Yu J, Horberg MA, et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015;24:1167–73.

Article  Google Scholar 

Levinson KL, Riedel DJ, Ojalvo LS, Chan W, Azngarita AM, Fader AN, et al. Gynecologic cancer in HIV infected women: treatment and outcomes in a multi-institutional cohort. AIDS. 2017;1.

Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163:507.

Article  Google Scholar 

Riedel DJ, Stafford KA, Vadlamani A, Redfield RR. Virologic and immunologic outcomes in HIV-infected patients with cancer. AIDS Res Hum Retroviruses. 2017;33:482–9. This study analyzed data from an urban clinic in Baltimore on the virologic and immunologic outcomes, after a cancer diagnosis, by comparing NADCs and ADCs in PLWH or uninfected cancer patients. Patients with NADCs had virologic suppression at baseline, and viral load suppression continued to be higher in PLWH and NADCs than PLWH and ADCs, indicating an emphasis of early ART initiation and continued engagement in HIV care.

Bulsara SM, Wainberg ML, Newton-John TRO. Predictors of adult retention in HIV care: a systematic review. AIDS Behav. 2018;22:752–64.

Article  Google Scholar 

Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26:1027–32.

Article  Google Scholar 

Kelley CF, Kitchen CMR, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. Incomplete peripheral CD4 + cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48:787–94.

Article  Google Scholar 

Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, et al. Association of early HIV viremia with mortality after HIV-associated lymphoma. AIDS. 2013;27:2365–73.

CAS  Article  Google Scholar 

Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. JNCI J Natl Cancer Inst. 2013;105:1221–9.

Article  Google Scholar 

Chao C, Xu L, Abrams D, Leyden W, Horberg M, Towner W, et al. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy: AIDS. 2010;24:1765–1770.

Calkins KL, Chander G, Joshu CE, Visvanathan K, Fojo AT, Lesko CR, et al. Immune status and associated mortality after cancer treatment among individuals with HIV in the antiretroviral therapy era. JAMA Oncol. 2020;6:227.

Article  Google Scholar 

Riedel DJ, Mwangi EIW, Fantry LE, Alexander C, Hossain MB, Pauza CD, et al. High cancer-related mortality in an urban, predominantly African-American. HIV-infected population. AIDS Lond Engl. 2013;27:1109–17.

Article  Google Scholar 

Hoang T, Goetz MB, Yano EM, Rossman B, Anaya HD, Knapp H, et al. The impact of integrated HIV care on patient health outcomes. Med Care. 2009;47:560–7.

Article  Google Scholar 

Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017;35:3737–44.

CAS  Article  Google Scholar 

Research C for DE and. Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections [Internet]. US Food Drug Adm. FDA; 2020 [cited 2021 Apr 14]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-hiv-hepatitis-b-virus-or-hepatitis-c-virus